• Je něco špatně v tomto záznamu ?

N-acetyl-D-glucosamine substituted calix[4]arenes as stimulators of NK cell-mediated antitumor immune response

Krenek K., Kuldová M., Hulíková K., Stibor I., Lhoták P., Dudic M., Budka J., Pelantová H., Bezouska K., Fiserová A., Kren V.

. 2007 ; 342 (12-13) : 1781-1792.

Jazyk angličtina Země Nizozemsko

Perzistentní odkaz   https://www.medvik.cz/link/bmc10000963

A series of calixarenes substituted with 2-acetamido-2-deoxy-beta-D-glucopyranose linked by a thiourea spacer was prepared and tested for binding activity to heterogeneously expressed activation receptors of the rat natural killer cells NKR-P1, and the receptor CD69 (human NK cells, macrophages). In the case of NKR-P1, the binding affinity of beta-D-GlcNAc-substituted calixarenes carrying two or four sugar units was in a good agreement with the inhibitory potencies of the linear chitooligomers (chitobiose to chitotetraose) reported previously. The influence of GlcNAc substitution of the calixarene skeleton on binding affinity for CD69 receptor was more profound and the 5,11,17,23-tetrakis[N-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-thioureido]-25,26,27,28-tetrapropoxycalix[4]arene (cone) (1) proved to be the best CD69 ligand identified to date. Lower GlcNAc substitution led to dramatic decrease of the binding activity (by about 1.5 order of magnitude per one GlcNAc unit). The immunostimulating activity results with the newly synthesized GlcNAc tetramers on calixarene scaffolds exhibited stimulation of natural cytotoxicity of human PBMC in concentrations 10(-4) and 10(-8)M. These calix-sugar compounds were superior to the previously tested PAMAM-GlcNAc(8)5.

000      
00000naa 2200000 a 4500
001      
bmc10000963
003      
CZ-PrNML
005      
20121003100925.0
008      
100115s2007 ne e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Křenek, Karel $7 xx0122428
245    10
$a N-acetyl-D-glucosamine substituted calix[4]arenes as stimulators of NK cell-mediated antitumor immune response / $c Krenek K., Kuldová M., Hulíková K., Stibor I., Lhoták P., Dudic M., Budka J., Pelantová H., Bezouska K., Fiserová A., Kren V.
314    __
$a Institute of Microbiology, Academy of Sciences of the Czech Republic, Vídenská 1083, 142 20 Praha 4, Czech Republic
520    9_
$a A series of calixarenes substituted with 2-acetamido-2-deoxy-beta-D-glucopyranose linked by a thiourea spacer was prepared and tested for binding activity to heterogeneously expressed activation receptors of the rat natural killer cells NKR-P1, and the receptor CD69 (human NK cells, macrophages). In the case of NKR-P1, the binding affinity of beta-D-GlcNAc-substituted calixarenes carrying two or four sugar units was in a good agreement with the inhibitory potencies of the linear chitooligomers (chitobiose to chitotetraose) reported previously. The influence of GlcNAc substitution of the calixarene skeleton on binding affinity for CD69 receptor was more profound and the 5,11,17,23-tetrakis[N-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-thioureido]-25,26,27,28-tetrapropoxycalix[4]arene (cone) (1) proved to be the best CD69 ligand identified to date. Lower GlcNAc substitution led to dramatic decrease of the binding activity (by about 1.5 order of magnitude per one GlcNAc unit). The immunostimulating activity results with the newly synthesized GlcNAc tetramers on calixarene scaffolds exhibited stimulation of natural cytotoxicity of human PBMC in concentrations 10(-4) and 10(-8)M. These calix-sugar compounds were superior to the previously tested PAMAM-GlcNAc(8)5.
650    _2
$a financování organizované $7 D005381
650    _2
$a acetylglukosamin $x analogy a deriváty $x farmakologie $7 D000117
650    _2
$a protinádorové látky $x farmakologie $x chemická syntéza $7 D000970
650    _2
$a kalixareny $x chemie $7 D047250
650    _2
$a glykokonjugáty $x chemická syntéza $x terapeutické užití $7 D006001
650    _2
$a lidé $7 D006801
650    _2
$a buňky NK $x imunologie $x účinky léků $7 D007694
650    _2
$a kinetika $7 D007700
650    _2
$a leukocyty mononukleární $x účinky léků $7 D007963
650    _2
$a aktivace lymfocytů $x účinky léků $7 D008213
650    _2
$a molekulární modely $7 D008958
650    _2
$a molekulární konformace $7 D008968
650    _2
$a nádory $x farmakoterapie $x imunologie $7 D009369
650    _2
$a T-lymfocyty $x imunologie $7 D013601
700    1_
$a Kuldová, Markéta. $7 _AN042532
700    1_
$a Hulíková, Katarína. $7 _AN043256
700    1_
$a Stibor, Ivan, $d 1944- $7 mzk2004261066
700    1_
$a Lhoták, Pavel $7 xx0064138
700    1_
$a Dudič, Miroslav. $7 ntk2013789963
700    1_
$a Budka, Jan $7 xx0125666
700    1_
$a Pelantová, Helena $7 xx0141862
700    1_
$a Bezouška, Karel, $d 1960- $7 jo2005273852
700    1_
$a Fišerová, Anna $7 xx0074790
700    1_
$a Křen, Vladimír $7 xx0070803
773    0_
$w MED00001049 $t Carbohydrate research $g Roč. 342, č. 12-13 (2007), s. 1781-1792 $x 0008-6215
910    __
$a ABA008 $b x $y 8
990    __
$a 20100114083259 $b ABA008
991    __
$a 20121003101113 $b ABA008
999    __
$a ok $b bmc $g 703691 $s 566132
BAS    __
$a 3
BMC    __
$a 2007 $b 342 $c 12-13 $d 1781-1792 $i 0008-6215 $m Carbohydrate research $x MED00001049
LZP    __
$a 2010-b1/vtme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...